Yesterday, May 3, 2016, 71 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $503.53 to $7,621,855.35. Highlighted Stocks Traded by Insiders: athenahealth (ATHN) - FREE Research Report Hull Brandon H, who is Director at athenahealth, sold 800 shares at $132.74 on May 3, 2016. Following this transaction, the Director owned 7,987 shares meaning that the stake was reduced by 9.1% with the 800-share transaction. The shares most recently traded at $127.84, down $4.90, or 3.83% since the insider transaction. Historical insider transactions for athenahealth go as follows:

  • 4-Week # shares sold: 2,047
  • 12-Week # shares sold: 10,131
  • 24-Week # shares sold: 20,401

The average volume for athenahealth has been 428,900 shares per day over the past 30 days. Athenahealth has a market cap of $5.2 billion and is part of the technology sector and computer software & services industry. Shares are down 20.39% year-to-date as of the close of trading on Tuesday. athenahealth, Inc., together with its subsidiaries, provides cloud-based services and mobile applications for medical groups and health systems. The company provides services through athenaNet, a cloud-based platform. The company has a P/E ratio of 232.7. Currently, there are 11 analysts who rate athenahealth a buy, 3 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATHN - FREE

TheStreet Quant Ratings

rates athenahealth as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including premium valuation and unimpressive growth in net income. Get the full

athenahealth Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ligand Pharmaceuticals (LGND) - FREE Research Report

Kozarich John W, who is Director at Ligand Pharmaceuticals, sold 1,000 shares at $121.57 on May 3, 2016. Following this transaction, the Director owned 43,711 shares meaning that the stake was reduced by 2.24% with the 1,000-share transaction. The shares most recently traded at $119.23, down $2.34, or 1.96% since the insider transaction. Historical insider transactions for Ligand Pharmaceuticals go as follows:

  • 4-Week # shares bought: 275
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 275
  • 12-Week # shares sold: 9,833
  • 24-Week # shares bought: 275
  • 24-Week # shares sold: 9,833

The average volume for Ligand Pharmaceuticals has been 425,200 shares per day over the past 30 days. Ligand Pharmaceuticals has a market cap of $2.6 billion and is part of the health care sector and drugs industry. Shares are up 10.59% year-to-date as of the close of trading on Tuesday. Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines worldwide. The company has a P/E ratio of 10.2. Currently, there are 4 analysts who rate Ligand Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LGND - FREE

TheStreet Quant Ratings

rates Ligand Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, notable return on equity, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Ligand Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Altisource Portfolio Solutions (ASPS) - FREE Research Report

Wilcox Kevin James, who is Chief Administration Officer at Altisource Portfolio Solutions, bought 1,700 shares at $29.36 on May 3, 2016. Following this transaction, the Chief Administration Officer owned 55,010 shares meaning that the stake was boosted by 3.19% with the 1,700-share transaction. The shares most recently traded at $28.72, down $0.64, or 2.24% since the insider transaction. Historical insider transactions for Altisource Portfolio Solutions go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 15,460
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 15,460
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 15,460

The average volume for Altisource Portfolio Solutions has been 845,300 shares per day over the past 30 days. Altisource Portfolio Solutions has a market cap of $545.3 million and is part of the services sector and diversified services industry. Shares are up 7.05% year-to-date as of the close of trading on Tuesday. Altisource Portfolio Solutions S.A. operates as a marketplace and transaction solutions provider for the real estate, mortgage, and consumer debt industries in the United States. The company has a P/E ratio of 10.7. Currently, there is 1 analyst who rates Altisource Portfolio Solutions a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASPS - FREE

TheStreet Quant Ratings

rates Altisource Portfolio Solutions as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and feeble growth in the company's earnings per share. Get the full

Altisource Portfolio Solutions Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.